Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000756824 | Cervix | N_HPV | aging | 21/534 | 339/18723 | 7.77e-04 | 9.73e-03 | 21 |
GO:0090136 | Cervix | N_HPV | epithelial cell-cell adhesion | 4/534 | 17/18723 | 1.16e-03 | 1.31e-02 | 4 |
GO:003109922 | Cervix | N_HPV | regeneration | 14/534 | 198/18723 | 1.69e-03 | 1.72e-02 | 14 |
GO:00085843 | Cervix | N_HPV | male gonad development | 11/534 | 141/18723 | 2.40e-03 | 2.18e-02 | 11 |
GO:00465463 | Cervix | N_HPV | development of primary male sexual characteristics | 11/534 | 142/18723 | 2.54e-03 | 2.28e-02 | 11 |
GO:004860822 | Cervix | N_HPV | reproductive structure development | 23/534 | 424/18723 | 2.58e-03 | 2.31e-02 | 23 |
GO:006145823 | Cervix | N_HPV | reproductive system development | 23/534 | 427/18723 | 2.81e-03 | 2.45e-02 | 23 |
GO:000704323 | Cervix | N_HPV | cell-cell junction assembly | 11/534 | 146/18723 | 3.15e-03 | 2.64e-02 | 11 |
GO:200123624 | Cervix | N_HPV | regulation of extrinsic apoptotic signaling pathway | 11/534 | 151/18723 | 4.07e-03 | 3.17e-02 | 11 |
GO:005127112 | Cervix | N_HPV | negative regulation of cellular component movement | 20/534 | 367/18723 | 4.53e-03 | 3.40e-02 | 20 |
GO:00107212 | Cervix | N_HPV | negative regulation of cell development | 12/534 | 180/18723 | 5.61e-03 | 3.98e-02 | 12 |
GO:200014612 | Cervix | N_HPV | negative regulation of cell motility | 19/534 | 359/18723 | 7.54e-03 | 4.89e-02 | 19 |
GO:00466613 | Cervix | N_HPV | male sex differentiation | 11/534 | 165/18723 | 7.83e-03 | 4.97e-02 | 11 |
GO:0007015 | Colorectum | AD | actin filament organization | 167/3918 | 442/18723 | 1.65e-16 | 7.94e-14 | 167 |
GO:0045216 | Colorectum | AD | cell-cell junction organization | 80/3918 | 200/18723 | 5.57e-10 | 4.58e-08 | 80 |
GO:0034329 | Colorectum | AD | cell junction assembly | 136/3918 | 420/18723 | 2.02e-08 | 1.15e-06 | 136 |
GO:2001233 | Colorectum | AD | regulation of apoptotic signaling pathway | 119/3918 | 356/18723 | 2.14e-08 | 1.21e-06 | 119 |
GO:1900180 | Colorectum | AD | regulation of protein localization to nucleus | 55/3918 | 136/18723 | 1.70e-07 | 7.34e-06 | 55 |
GO:0007043 | Colorectum | AD | cell-cell junction assembly | 57/3918 | 146/18723 | 4.18e-07 | 1.61e-05 | 57 |
GO:0007163 | Colorectum | AD | establishment or maintenance of cell polarity | 77/3918 | 218/18723 | 5.72e-07 | 2.08e-05 | 77 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0452020 | Cervix | CC | Adherens junction | 33/1267 | 93/8465 | 6.99e-07 | 7.31e-06 | 4.32e-06 | 33 |
hsa0467020 | Cervix | CC | Leukocyte transendothelial migration | 36/1267 | 114/8465 | 5.22e-06 | 4.83e-05 | 2.86e-05 | 36 |
hsa043908 | Cervix | CC | Hippo signaling pathway | 40/1267 | 157/8465 | 3.64e-04 | 1.82e-03 | 1.07e-03 | 40 |
hsa0510020 | Cervix | CC | Bacterial invasion of epithelial cells | 23/1267 | 77/8465 | 6.25e-04 | 2.93e-03 | 1.73e-03 | 23 |
hsa0521310 | Cervix | CC | Endometrial cancer | 18/1267 | 58/8465 | 1.46e-03 | 6.30e-03 | 3.73e-03 | 18 |
hsa04520110 | Cervix | CC | Adherens junction | 33/1267 | 93/8465 | 6.99e-07 | 7.31e-06 | 4.32e-06 | 33 |
hsa04670110 | Cervix | CC | Leukocyte transendothelial migration | 36/1267 | 114/8465 | 5.22e-06 | 4.83e-05 | 2.86e-05 | 36 |
hsa0439013 | Cervix | CC | Hippo signaling pathway | 40/1267 | 157/8465 | 3.64e-04 | 1.82e-03 | 1.07e-03 | 40 |
hsa05100110 | Cervix | CC | Bacterial invasion of epithelial cells | 23/1267 | 77/8465 | 6.25e-04 | 2.93e-03 | 1.73e-03 | 23 |
hsa0521313 | Cervix | CC | Endometrial cancer | 18/1267 | 58/8465 | 1.46e-03 | 6.30e-03 | 3.73e-03 | 18 |
hsa0467025 | Cervix | HSIL_HPV | Leukocyte transendothelial migration | 16/459 | 114/8465 | 4.04e-04 | 3.49e-03 | 2.82e-03 | 16 |
hsa054127 | Cervix | HSIL_HPV | Arrhythmogenic right ventricular cardiomyopathy | 10/459 | 77/8465 | 8.34e-03 | 4.70e-02 | 3.80e-02 | 10 |
hsa0467035 | Cervix | HSIL_HPV | Leukocyte transendothelial migration | 16/459 | 114/8465 | 4.04e-04 | 3.49e-03 | 2.82e-03 | 16 |
hsa0541212 | Cervix | HSIL_HPV | Arrhythmogenic right ventricular cardiomyopathy | 10/459 | 77/8465 | 8.34e-03 | 4.70e-02 | 3.80e-02 | 10 |
hsa0510025 | Cervix | N_HPV | Bacterial invasion of epithelial cells | 10/349 | 77/8465 | 1.17e-03 | 7.93e-03 | 6.20e-03 | 10 |
hsa0467045 | Cervix | N_HPV | Leukocyte transendothelial migration | 12/349 | 114/8465 | 2.50e-03 | 1.45e-02 | 1.13e-02 | 12 |
hsa0510035 | Cervix | N_HPV | Bacterial invasion of epithelial cells | 10/349 | 77/8465 | 1.17e-03 | 7.93e-03 | 6.20e-03 | 10 |
hsa0467055 | Cervix | N_HPV | Leukocyte transendothelial migration | 12/349 | 114/8465 | 2.50e-03 | 1.45e-02 | 1.13e-02 | 12 |
hsa05100 | Colorectum | AD | Bacterial invasion of epithelial cells | 44/2092 | 77/8465 | 1.13e-09 | 2.22e-08 | 1.42e-08 | 44 |
hsa04520 | Colorectum | AD | Adherens junction | 50/2092 | 93/8465 | 1.52e-09 | 2.83e-08 | 1.81e-08 | 50 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CTNNA1 | SNV | Missense_Mutation | rs781520852 | c.160N>T | p.Arg54Cys | p.R54C | P35221 | protein_coding | tolerated(0.07) | possibly_damaging(0.873) | TCGA-AC-A3TM-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | CR |
CTNNA1 | SNV | Missense_Mutation | | c.1294G>C | p.Glu432Gln | p.E432Q | P35221 | protein_coding | tolerated(0.07) | benign(0.405) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
CTNNA1 | SNV | Missense_Mutation | | c.1673C>T | p.Ser558Leu | p.S558L | P35221 | protein_coding | deleterious(0) | benign(0.295) | TCGA-BH-A18U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
CTNNA1 | insertion | Nonsense_Mutation | novel | c.451_452insAACAAATAAAAGAATGAATGATCTCCATCT | p.Leu151delinsGlnGlnIleLysGluTerMetIleSerIlePhe | p.L151delinsQQIKE*MISIF | P35221 | protein_coding | | | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
CTNNA1 | SNV | Missense_Mutation | | c.2350G>A | p.Ala784Thr | p.A784T | P35221 | protein_coding | tolerated(0.41) | benign(0.131) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CTNNA1 | SNV | Missense_Mutation | novel | c.2411G>A | p.Gly804Asp | p.G804D | P35221 | protein_coding | deleterious(0.01) | possibly_damaging(0.756) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
CTNNA1 | SNV | Missense_Mutation | | c.1939N>C | p.Asp647His | p.D647H | P35221 | protein_coding | deleterious(0.01) | probably_damaging(0.95) | TCGA-EK-A2RA-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
CTNNA1 | SNV | Missense_Mutation | novel | c.2163N>C | p.Met721Ile | p.M721I | P35221 | protein_coding | deleterious(0.04) | possibly_damaging(0.516) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
CTNNA1 | SNV | Missense_Mutation | novel | c.1027G>A | p.Ala343Thr | p.A343T | P35221 | protein_coding | deleterious(0.02) | benign(0.12) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
CTNNA1 | SNV | Missense_Mutation | | c.2397N>T | p.Glu799Asp | p.E799D | P35221 | protein_coding | tolerated(0.88) | benign(0.071) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |